Pharmafile Logo

primary membranous nephropathy

- PMLiVE

Roche’s Gazyva/Gazyvaro approved by FDA for primary membranous nephropathy

This rare, chronic autoimmune disease can cause kidney failure if left untreated

- PMLiVE

Medscape Education Wins “Partner of Hope Award” for Scleroderma Advocacy

Medscape Education receives National Scleroderma Foundation’s Rocky Mountain Chapter's “Partner of Hope Award” for empowering the patient voice and shortening the diagnostic journey. This recognition honors Medscape Education’s significant commitment...

Medscape Education

- PMLiVE

Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

- PMLiVE

Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

- PMLiVE

Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn

The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases

- PMLiVE

Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments

MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain

- PMLiVE

FDA approves Priovant’s Lisraya for dermatomyositis

This is the first oral drug treatment for this rare disease in adults

- PMLiVE

FDA approves Revolution Medicines’ first in class targeted therapy for metastatic pancreatic cancer

67,000 new cases of pancreatic cancer are diagnosed in the US each year

- PMLiVE

Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment

This is the first and only at-home subcutaneous treatment option for this disease

- PMLiVE

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

- PMLiVE

Roche and Nurix Therapeutics to partner in $2.3bn deal

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology

- PMLiVE

Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes

The treatment can be used to delay the onset of clinical type 1 diabetes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links